“Next-Level” Cell Therapy: New Targets, New Sources, New Possibilities. New Problems - Ron Chard Clinical Oncology Lecture
Objectives and Disclosures
Participants will be able to:
- outline recent advances in cancer cell and gene therapy at Texas Children’s Hospital
- analyze the unique challenges of novel cancer cell and gene therapies that make participation of underrepresented and under-resourced patients challenging
- assess strategies to intentionally increase access to early phase cancer cell and gene therapy clinical trials
Planners disclose they have no relevant financial relationships.
The speaker discloses: intent to reference the investigative use of cell and gene therapies targeting CD5, CD7, CD30, CD19 and EBV antigens. Speaker also discloses: honoraria from Novartis, consultant for Pfizer, receives grant/research support from Tessa Therapeutics.
All relevant financial relationships have been mitigated.
Rayne Rouce, MD, BS
Assistant Professor, Pediatrics Hematology Oncology Education, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Physician, Texas Children's Cancer Center, Bone Marrow Transplant/Stem Cell Transplant Program
Seattle Children’s is accredited by the Washington State Medical Association CME Accreditation Committee to sponsor continuing medical education for physicians.
Seattle Children’s designates this online educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 1 hour of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Videos are available for only one year after posting.
If you wish to receive Category I CME credit for viewing this Provider Grand Rounds session, please complete the evaluation form. Upon completion of the form you will receive an auto-reply email that will serve as the only confirmation of your CME credit. Please keep the email for your records.